Masters Series Mechanical Heart Valve
ABBOTT MEDICAL · Decision date Oct 15, 2025
What did the FDA decide?
FDA records P810002/S125 as a supplement to PMA P810002, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 15, 2025.
FDA approval order statement
a change to the endotoxin extraction sample preparation method and to add the PyroGene endotoxin test method to detect bacterial endotoxins
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 15, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P810002/S125
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- LWQ
- Decision code
- OK30
- Decision date
- Oct 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: HEART-VALVE, MECHANICAL.
- Applicant
- Abbott Medical
- Product code
- LWQ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P810002/S125 received
Application receipt date recorded by FDA.
P810002/S125 · FDA decision
30-Day Notice
P810002/S126 · Related supplement
Masters Series Aortic Valved Graft with Hemashield Graft Technology (CAVGJ)
Timeline entries are records held by MedtechLedger for P810002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P810002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Jun 11, 2026 | FDA |
Explore the linked device profile
Other records with product code LWQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| On-X Life Technologies, Inc. | PMA supplement | Aug 4, 2026 | FDA | |
| Corcym S.r.l. | PMA supplement | Jul 28, 2026 | FDA | |
| On-X Life Technologies, Inc. | PMA supplement | Jul 27, 2026 | FDA | |
| On-X Life Technologies, Inc. | PMA supplement | Jan 5, 2026 | FDA | |
On-X Ascending Aortic ProsthesisP000037/S067 | On-X Life Technologies, Inc. | PMA supplement | Dec 17, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 177 County Rd. B E., St. Paul, MN, 55117
Sources and methodology
- Original FDA record: P810002/S125
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
